|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000014836 |
|
Date of registration:
|
12/08/2014 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
A pilot study to evaluate efficacy and safety of resveratrol for muscular dystrophy.
|
|
Scientific title:
|
A pilot study to evaluate efficacy and safety of resveratrol for muscular dystrophy. - A pilot study of resveratrol for muscular dystrophy. |
|
Date of first enrolment:
|
2014/05/01 |
|
Target sample size:
|
10 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016656 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Kentaro Kawamura |
|
Address:
|
South 1 West 16, Chuo-ku, Sapporo, Japan
Japan |
|
Telephone:
|
011-611-2111 |
|
Email:
|
k.kawamura@sapmed.ac.jp |
|
Affiliation:
|
Sapporo Medical University Department of Pediatrics |
|
|
Name:
|
Yoshiyuki Horio |
|
Address:
|
South 1 West 16, Chuo-ku, Sapporo, Japan
Japan |
|
Telephone:
|
011-611-2111 |
|
Email:
|
horio@sapmed.ac.jp |
|
Affiliation:
|
Sapporo Medical University Department of Pharmacology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: 1) Hypersensitivity to resveratrol. 2) Disqualified for trial by principal investigator.
Age minimum:
12years-old
Age maximum:
Not applicable
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Duchenne muscular dystrophy, Becker muscular dystrophy, Fukuyama congenital muscular dystrophy
|
|
Intervention(s)
|
|
500mg resveratrol is administrated daily for 8 weeks. Subsequently, resveratrol is increased to 1500mg by 500mg every 8 weeks.
|
|
Primary Outcome(s)
|
|
Muscular strength, motor function and muscular injury marker befor and after adoministratation of resveratrol.
|
|
Secondary Outcome(s)
|
|
Advers events.
|
|
Source(s) of Monetary Support
|
|
Department of Pharmacology, Sapporo Medical University
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
|
|
Date Completed:
|
29/09/2015 |
|
URL:
|
|
|
|